Unitree Robotics clears Shanghai IPO hearing, targets $621M raise
Synopsis
Key Takeaways
Unitree Robotics, one of mainland China's leading humanoid robot makers, cleared a listing committee hearing on Monday, June 1, 2026, removing a critical barrier to its initial public offering on Shanghai's Star Market. The Hangzhou-based firm now moves closer to registration and issuance after surviving two rounds of regulatory inquiries and an on-site inspection.
The IPO Details
Unitree originally filed to list on the Star Market on March 20, seeking to raise 4.2 billion yuan (US$621 million) by offering at least 40.4 million shares, representing a minimum 10 per cent stake in the company. The hearing approval formally opens the path to registration and share issuance, the final procedural steps before trading can begin.
Financial Standing Among Peers
Unitree generated 1.7 billion yuan in revenue last year, trailing Hong Kong-listed UBTech's 2 billion yuan. However, the company posted the highest net profit among its peers at 590.8 million yuan, signalling stronger operational efficiency that is likely to attract institutional attention during the roadshow.
The Competitive Backdrop
The listing positions Unitree at the vanguard of a broader humanoid robot IPO wave sweeping China's capital markets. Dobot, already listed in Hong Kong, is pursuing a dual listing on Shenzhen's ChiNext board, while Leju Robotics and Deep Robotics are also advancing towards IPOs in Shenzhen and Shanghai, respectively.
Why It Matters
'The humanoid IPO wave will raise market interest in robotics equities,' said Zhong Sheng, head of China industrials research at Morgan Stanley. As a bellwether for the sector, Unitree's listing is being closely watched by investors seeking exposure to China's state-backed push into intelligent manufacturing and embodied AI.
What's Next
With hearing approval secured, Unitree must now complete registration with securities regulators before setting a pricing date and launch timeline. The outcome of its roadshow and final valuation will serve as a critical pricing benchmark for the cluster of humanoid robot companies queued behind it on China's domestic exchanges.